120
Participants
Start Date
January 1, 2020
Primary Completion Date
December 31, 2023
Study Completion Date
December 31, 2025
Ibrutinib
Ibrutinib 560 mg/day daily (starting dose) between days 4 and 28 of each cycle for six cycles. Then Ibrutinib is continued until disease progression, intolerable toxicity, death or up to two years.
Lenalidomide
Oral lenalidomide 25mg/day between days 4 and 24 of each cycle for six cycles. Then lenalidomide is continued until disease progression, intolerable toxicity, death or up to two years.
Methotrexate
Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min + 3 g/m2 in 3-hr infusion) on day 1
Rituximab
Rituximab 375 mg/m2 conventional infusion on day 1
Etoposide
Etoposide 250 mg/m2 over 3 hours on day3
PEGylated recombinant human granulocyte colony
PEGylated recombinant human granulocyte colony 100 ug/kg subcutaneous injection on day 5.
RECRUITING
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
Ruijin Hospital
OTHER
The First Affiliated Hospital of Nanchang University
OTHER
Fujian Medical University Union Hospital
OTHER
RenJi Hospital
OTHER
Shanghai Tong Ren Hospital
OTHER
Shandong Provincial Hospital
OTHER_GOV
Cancer Hospital of Guangxi Medical University
OTHER
Sir Run Run Shaw Hospital
OTHER
Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
OTHER
Ningbo Medical Center Lihuili Hospital
OTHER_GOV
Yinzhou Hospital Affiliated to Medical School of Ningbo University
OTHER
Zhejiang University
OTHER
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER